Genes at the crossroad of primary immunodeficiencies and cancer

15Citations
Citations of this article
57Readers
Mendeley users who have this article in their library.

Abstract

Primary immunodeficiencies (PIDs) are a heterogeneous group of inherited disorders affecting one or multiple components of the innate and/or adaptive immune system. Currently, over 300 underlying genetic defects have been discovered. The most common clinical findings in patients with PIDs are infections, autoimmunity, and malignancies. Despite international efforts, the cancer risk associated with PIDs, given the heterogeneous character of this group of diseases, is difficult to estimate. The diverse underlying mechanisms of cancer in PID add another layer of complexity. Treatment of cancer within a context of PID is complicated by serious toxicities and long-term effects, including second malignancies. This review will focus on the little-known crossroad between PID and cancer genes and the value thereof for directing future research on our understanding of cancer in PID and for the identification of early cancer biomarkers in PID patients.

Cite

CITATION STYLE

APA

Derpoorter, C., Bordon, V., Laureys, G., Haerynck, F., & Lammens, T. (2018, November 1). Genes at the crossroad of primary immunodeficiencies and cancer. Frontiers in Immunology. Frontiers Media S.A. https://doi.org/10.3389/fimmu.2018.02544

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free